Screener Summaries Updates Institutions Sign In More Updates › Earnings › BIIB Earnings · Jan 14, 2026
Biogen expects to incur approximately $222 million in pre-tax acquired in-process research and development, upfront… BIIB Biogen Inc.
Biogen expects to incur approximately $222 million in pre-tax acquired in-process research and development, upfront, and milestone expenses for the fourth quarter of 2025. This charge is anticipated to reduce both GAAP and non-GAAP net income per diluted share by approximately $1.26. This significant one-time expense will weigh on the company's reported earnings for the quarter.
More from Biogen Inc. Biogen reports Q3 revenue of $2.8B, up 11%, and raises full-year Non-GAAP EPS guidance to $12.20-$13.00 Oct 28, 2026 Biogen Inc. reported second quarter 2026 financial results with total revenue of $2.7 billion, a 3% year-over-year… Jul 29, 2026 Biogen Inc. expects to incur approximately $164 million in pre-tax acquired in-process research and development… Jul 1, 2026 Biogen Inc. filed this amendment to its May 14, 2026, Form 8-K to clarify that the acquisition of Apellis… Jun 10, 2026 Biogen has completed its acquisition of Apellis Pharmaceuticals for approximately $5.3 billion, funded in part by a… May 14, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
